Literature DB >> 12820694

CD45 isoform expression in autoimmune myasthenia gravis.

B Tackenberg1, M Nitschke, N Willcox, A Ziegler, S Nessler, F Schumm, W H Oertel, B Hemmer, N Sommer.   

Abstract

In myasthenia gravis (MG), humoral and cellular immune mechanisms are involved in the autoimmune pathogenesis. In this study, we investigated the role of the CD45 molecule in MG, having recently reported an association in multiple sclerosis. CD45, a protein-tyrosine phophatase receptor type C (PTPRC), is essential for both thymic selection and peripheral activation of T and B cells. Our aims were to determine (a) the prevalence of a functional mutation in the CD45 gene (exon 4 77C --> G; prevalence analysis), and (b) the distribution of memory (CD45RO+) and naive (CD45RA+) T cells in the peripheral blood (subset analysis). T cells from 78 patients with generalised MG were stained with monoclonal antibodies against CD45RO, CD45RA, CD4 and CD8 and quantified by four-colour flow cytometry. The control panel for the prevalence analysis (a) consisted of 303 healthy individuals. (b) From those, 67 age- and sex-matched probands were randomly selected as controls for the subset analysis. Patients were stratified according to their MG onset age, thymic pathology and immunosuppressive treatment. Statistical analysis was performed by Fisher's exact test, asymptotic chi2 test, the two-sided Mann-Whitney test and Spearman's correlation coefficient. As a result, the 77C --> G mutation in exon 4 of the CD45 gene was found in 1 of 78 patients versus none of the 303 controls. Thus, no association was detected with this single nucleotide polymorphism in MG patients overall. Surprisingly, however, ratios of CD45RO+ to CD45RA+ T cells were lower among CD8+ T cells from patients with late-onset MG (P = 0.023). Thymoma patients also showed a similar trend among CD4+ and CD8+ T-cells, as expected. These differences were not related to immunosuppressive drug treatment or thymectomy (in the 67 informative patients). Since there is no other evidence for increased thymopoiesis in late-onset MG, we propose an altered subset balance in the circulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820694     DOI: 10.1080/0891693031000084369

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  6 in total

1.  Combinatorial control of signal-induced exon repression by hnRNP L and PSF.

Authors:  Alexis A Melton; Jason Jackson; Jiarong Wang; Kristen W Lynch
Journal:  Mol Cell Biol       Date:  2007-07-30       Impact factor: 4.272

2.  Unusual case presentations associated with the CD45 C77G polymorphism.

Authors:  E Z Tchilian; J Gil; M L Navarro; E Fernandez-Cruz; H Chapel; S Misbah; B Ferry; H Renz; R Schwinzer; P C L Beverley
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

3.  N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death.

Authors:  Lesley A Earl; Shuguang Bi; Linda G Baum
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

4.  A cell-based screen for splicing regulators identifies hnRNP LL as a distinct signal-induced repressor of CD45 variable exon 4.

Authors:  Justin D Topp; Jason Jackson; Alexis A Melton; Kristen W Lynch
Journal:  RNA       Date:  2008-08-21       Impact factor: 4.942

5.  The CD45 77C/G allele is not associated with myasthenia gravis - a reassessment of the potential role of CD45 in autoimmunity.

Authors:  Ryan Ramanujam; Ritva Pirskanen; Lennart Hammarström
Journal:  BMC Res Notes       Date:  2010-11-10

Review 6.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.